Status:
COMPLETED
A Clinical Trial to Evaluate the Efficacy of a Men's Supplement in Supporting Testosterone, Improving Cognitive Function, Mood, and Sexual Function
Lead Sponsor:
Scale Media Inc
Collaborating Sponsors:
Citruslabs
Conditions:
Sexual Function
Cognitive Functions
Eligibility:
MALE
30-65 years
Phase:
NA
Brief Summary
This randomized, triple-blind, placebo-controlled, hybrid trial aims to evaluate the efficacy of a men's supplement designed to increase testosterone levels and improve energy, cognition, and sexual f...
Eligibility Criteria
Inclusion
- Male (biological at birth).
- Aged between 30-65.
- Generally healthy - do not live with any uncontrolled chronic disease such as diabetes or hypertension.
- Willing to provide blood draws during the study duration.
- Fitness/wellness enthusiast who has the same weekly exercise routine i.e. HIIT, strength training, or running \>3 times per week.
- Self-reported concerns with energy levels, mood, and libido and sexual performance/adequacy.
- Willing to avoid medications, supplements, or vitamins aimed at increasing testosterone levels for the duration of the study.
Exclusion
- Any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
- Anyone with known severe allergic reactions requiring the use of an Epi-Pen.
- Unwilling to follow the study protocol.
- Currently experiencing significant symptoms of a mental disorder that might interfere with study participation (e.g., eating disorder, obsessive-compulsive disorder, posttraumatic stress syndrome, bipolar disorder).
- Current substance abuse disorder.
- Any medical condition that is unstable or uncontrolled.
- Has introduced any new prescription medication or supplements within the past 12 weeks that influence testosterone production.
- History of testicular or prostate cancer.
- Previously has undergone a vasectomy.
- Currently undergoing hormone replacement therapy (HRT)
- Currently taking performance-enhancing drugs.
- Anyone taking prescription blood pressure, immunosuppressants, sleeping aids, anti-seizure, and/or thyroid medications.
- Living in New York, Rhode Island, Hawaii, or Alaska.
Key Trial Info
Start Date :
May 7 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06596928
Start Date
May 7 2024
End Date
September 1 2024
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Citruslabs
Santa Monica, California, United States, 90404